Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth episode artwork

EPISODE · Aug 12, 2023 · 14 MIN

Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

from ehealth radio network · host eHealth Radio Network

    Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels. Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following: What is unique about Actinium’s radiotherapy approach?Tell me about Iomab-B, its target population, and how it will affect the patient journey.Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?What’s next in your pipeline?Tell me what upcoming catalysts I should expect in the second half of 2023.About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications. Website: https://www.actiniumpharma.com Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc- Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-Inc Twitter: https://twitter.com/ActiniumPharma People also listened to this: The Miracle of Enzymes to Heal Digestive Problems

Episode metadata supplied by the publisher feed · Published Aug 12, 2023

Embed this episode

NOW PLAYING

Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

0:00 14:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of ehealth radio network?

This episode is 14 minutes long.

When was this ehealth radio network episode published?

This episode was published on August 12, 2023.

Can I download this ehealth radio network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!